Mostafa Faisal

Honored to be a part of this nice work; the first issue of Saudi Blood Clinical News covering the recent publications and info of recent approved FDA drugs in Hematology and SCT cn.saudiblood.org

1/ Our call to action is out in @BloodAdvances! Title speaks for itself. Given concerningly high infection risk with bsAbs in myeloma #MMsm, IVIG/SCIG should be started regardless of any IgG threshold. Global authors & global audience, including insurance & healthcare funders.

A proposed treatment algorithm of patients with LR-MDS in 2025 mdpi.com/2072-6694/17/1… #mds @Dr_AmerZeidan

A proposed treatment algorithm of patients with HR-MDS in 2025 mdpi.com/2072-6694/17/1… #mds @Dr_AmerZeidan

#Myeloma Paper of the Day: Study of myeloma patient preferences on clinical decision making concludes that many choose against treatments that improve PFS if they do not positively affect OS and lead to clinical, financial, and/or time toxicities: pubmed.ncbi.nlm.nih.gov/40705989/. #mmsm

Reconstructing CML guidelines for first line treatment from two different points of view @BloodCancerJnl nature.com/articles/s4140…

Uncommon Entities, Uncommon Challenges: A Review of Rare Plasma Cell Disorders ✔️By Myeloma team @KFSHRC mdpi.com/2038-8330/17/4…

Allogeneic haematopoietic stem cell transplantation in advanced cutaneous T-cell lymphomas offers curative potential @BMTjournal nature.com/articles/s4140…